tirzepatide gip mechanism of action (MOA) of tirzepatide gip receptor Dual Incretin

Are GLP-1 medications safe whilst breastfeeding

Common (affecting up to 1 in 10 people, usually settling after a few weeks) Uncommon or rare (affecting up to 1 in 100 - or 1 in 1000 if rare - people, contact a doctor if severe) Nausea, diarrhoea, constipation, indigestion, tummy pain, reduced appetite, vomiting, injection-site reactions, dizziness, hair loss Gallstones,pancreatitis (severe abdominal or back pain),injection-site pain, serious allergy, changed sense of taste, change in skin sensation

Much of the refractory pain and suffering from these conditions might be attributable to obesity, so active questions will be raised about how GLP-1 agonists can influence the diseases we treat.

While some parents have concerns, others see the medication as a "gift" for their children's health.

The gut microbiome influences many aspects of metabolic health including digestive signaling, short-chain fatty acid production, immune communication, and gut barrier integrity

Indulgence remains popular as well, but in a different way: GLP-1 users are driving growth in premium chocolate, for example.